Back to resultsN-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure
Primary Purpose
Acute Heart Failure, Acute Myocardial Infarction
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Epadel, Eicosapentaenoic acid
Sponsored by
About this trial
This is an interventional prevention trial for Acute Heart Failure
Eligibility Criteria
Inclusion Criteria:
- sinus rhythm patients with acute heart failure or acute myocardial infarction
Exclusion Criteria:
- pregnancy,allergy to epadel
Sites / Locations
Outcomes
Primary Outcome Measures
detection of atrial fibrillation on ECG monitoring
Secondary Outcome Measures
Full Information
NCT ID
NCT00692718
First Posted
May 29, 2008
Last Updated
June 18, 2008
Sponsor
Osaka General Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT00692718
Brief Title
N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure
Official Title
N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure
Study Type
Interventional
2. Study Status
Record Verification Date
June 2008
Overall Recruitment Status
Unknown status
Study Start Date
July 2008 (undefined)
Primary Completion Date
June 2010 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Osaka General Medical Center
4. Oversight
5. Study Description
Brief Summary
Our study is to investigate the effect of N-3 Fatty Acids for the prevention of atrial fibrillation in patients with acute heart failure or acute myocardial infarction
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Heart Failure, Acute Myocardial Infarction
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Epadel, Eicosapentaenoic acid
Intervention Description
Epadel 900mg, 2 times a day, during hospitalization
Primary Outcome Measure Information:
Title
detection of atrial fibrillation on ECG monitoring
Time Frame
anytime during hospitalization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
sinus rhythm patients with acute heart failure or acute myocardial infarction
Exclusion Criteria:
pregnancy,allergy to epadel
12. IPD Sharing Statement
Learn more about this trial
N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure
We'll reach out to this number within 24 hrs